![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, July 19, 2008 11:44:04 AM
Surely we don't need the butterfly effect to explain the precipitous drop in fan and fred pps? Their assets may well be (going to be) worth less than their liabilities in view of the house price meltdown. See Dean Baker on American Prospect if you're tired of Krugman's apologia for / minimization of the GSEs' irresponsibility.
Anyway, although Taleb happens to repeat the butterfly story uncritically, I thought it had been debunked as urban myth?
None of which invalidates profound skepticism about naked shorting. I would think that it is hard to manipulate thickly traded, well-followed stocks like the ones that the repellent Cox has suddenly begun to worry about - although creating a panic could work even under such conditions. (The fact that there are only 5 major brokers permits collusion or contagion thru groupthink, for example.) But usually if one crowd beats a price down there'll be smart (or dumb - we'll take sovereign funds) investors who see value and bid it back up again.
Not so in our little backwater. Manipulation conditions are excellent in general. And naked shorting turbo-charges the swamping effect of short attacks on retail longs. There are far too few potential longs following these little biotechs to take advantage of the ridiculous bargains that a few of them, like RPRX, represent. That becomes somewhat self-fulfilling when cash shortages strike. But this too shall pass. There are not many examples of high-potential pipeline drugs falling into acquirer hands for a song, nor of pipeline companies simply folding and the pipleine being abandoned like so much useless dotcom fiber. Or are there? Or will we see this happen soon?
Even poor little DORB, with its promising GVHD pill given the shaft by the psychopathic Pazdur, is still soldiering on. (Would it be worth a flutter again, btw? Has anyone looked to see if it has the cash to get another P3 done and NDA submitted? Or are they just getting round Pazdur by selling the pill for compassionate use?)
Zymo is not likely going to be prevented by the Oppenheimers et al and their stupid fixation on quarterly Recothrom revs - from developing atacicept and IL 21. Deerfield has probably ensured that, albeit by betting on quarterly Recothrom sales! If either of those drugs hits - or the lambda one that Clark likes - it's a jackpot for Zymo and the shorts can't stop it.
Recent RPRX News
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:25:01 PM
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million • GlobeNewswire Inc. • 05/28/2024 11:10:00 AM
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:10:00 PM
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM